Vol. 19/No. 20

The National Comprehensive Cancer Network has issued the first-ever guidelines for the treatment of women with gestational trophoblastic neoplasia.

Although CD19 has proved to be an attractive and effective target for chimeric antigen receptor T-cell therapies in hematologic malignancies, a significant subset of patients treated with this groundbreaking form of immunotherapy eventually relapse.

The presence of Lynch syndrome correlates with microsatellite-instability status and DNA mismatch-repair deficiency across a variety of tumor types.

A policy change that allows step therapy provisions in Medicare Advantage insurance plans is setting off alarm bells among oncology leaders, who have joined medical associations from across the country in objecting to the revision.

One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.

An increasing number of oncologists are choosing to specialize, affecting how patient care is delivered and the futures of small practices and large cancer clinics.

Since triple-negative breast cancer is resistant to multiple therapies, physicians have little flexibility for treatment options. However, anticipation is building for potential alternatives.

Maurie Markman, MD, discusses privacy concerns associated with genetic testing.